)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Day One Biopharmaceuticals
Day One Biopharmaceuticals (DAWN) investor relations material
Day One Biopharmaceuticals TD Cowen 46th Annual Health Care Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.TD Cowen 46th Annual Health Care Conference summary3 Mar, 2026
Key business highlights
Achieved over $155 million in revenue in 2025, marking 170% year-over-year growth, with Q4 revenue exceeding $52 million and 37% quarter-over-quarter growth.
Provided 2026 net product revenue guidance of $225–$250 million, targeting about 50% year-over-year growth at the midpoint.
OJEMDA is positioned as the main driver of durable growth, with ongoing expansion into new indications and pipeline programs.
Frontline trial enrollment for OJEMDA expected to complete in the first half of the year, with key data readouts anticipated.
Emphasized a strong, execution-focused team and seamless integration of new assets.
Product performance and launch metrics
New patient starts (NPS) grew 25% in the second half of 2025 compared to the first half, driven by additional data and physician education.
Duration of therapy averages 17 months (mean) and 19 months (median), supporting sustained growth.
Persistence is expected to improve with more data, physician experience, and better management of side effects like rash.
Second line use is increasing as familiarity grows, with education and data dissemination as key priorities.
Recent data show nearly 80% of children remain off therapy for a year after completing OJEMDA, with a median time to next therapy of almost 43 months.
Pipeline and R&D updates
DAY301 (PTK7-targeted ADC) began dose escalation in late 2024, with initial clinical data expected in the back half of 2025.
Early antitumor signals and a favorable safety profile observed, with plans to expand into tumor-specific cohorts.
Emi-Le (B7-H4-targeted ADC) for adenoid cystic carcinoma (ACC) will have updated data mid-year, focusing on safety and efficacy.
ACC chosen as the lead indication due to strong clinical data and urgent unmet need; TNBC remains a possible future target.
Emi-Le’s safety profile shows no hematologic, neuropathic, or ocular toxicity, which is notable for its class.
What is the ceiling for OJEMDA duration of therapy?
Quantify frontline trial's impact on peak sales.
What specific data supports Emi-Le's ACC focus?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next Day One Biopharmaceuticals earnings date
Leerink Global Healthcare Conference 202611 Mar, 2026
Day One Biopharmaceuticals
Next Day One Biopharmaceuticals earnings date
Leerink Global Healthcare Conference 202611 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Day One Biopharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancer patients. The company specializes in identifying and advancing therapies designed for patients with genetically defined cancers, particularly in pediatric and young adult populations. The company is headquartered in Brisbane, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage